Naomi Mizuno

The Intestinal First-pass Metabolism of Substrates of CYP3A4 and P-glycoprotei—Quantitative Analysis Based on Information from the Literature

Motohiro Kato, Kōji Chiba, Akihiro Hisaka et al. · Drug Metabolism and Pharmacokinetics · 2003 · 91 citations

Medicine, Pharmacokinetics, Pharmacology +13

IMPAIRED RENAL EXCRETION OF 6-HYDROXY-5,7-DIMETHYL-2-METHYLAMINO-4-(3-PYRIDYLMETHYL) BENZOTHIAZOLE (E3040) SULFATE IN BREAST CANCER RESISTANCE PROTEIN (BCRP1/ABCG2) KNOCKOUT MICE

Naomi Mizuno, Michiko Suzuki, Hiroyuki Kusuhara et al. · Drug Metabolism and Disposition · 2004 · 91 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Kiyomi Ito, Kōji Chiba, Masato Horikawa et al. · AAPS PharmSci · 2002 · 86 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Drug Transporters: Their Role and Importance in the Selection and Development of New Drugs

Naomi Mizuno, Yuichi Sugiyama · Drug Metabolism and Pharmacokinetics · 2002 · 76 citations

Medicine, Pharmacology, Drug Discovery +12

Evaluation of the Role of Breast Cancer Resistance Protein (BCRP/ABCG2) and Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in The Urinary Excretion of Sulfate and Glucuronide Metabolites of Edaravone (MCI-186; 3-Methyl-1-phenyl-2-pyrazolin-5-one)

Naomi Mizuno, Tsuyoshi Takahashi, Hiroyuki Kusuhara et al. · Drug Metabolism and Disposition · 2007 · 61 citations

Medicine, Pharmacokinetics, Pharmacology +13